SynthesisFrontiers in psychiatry2025
Early muscle hypotonia as a potential marker for autism spectrum disorder: a systematic review.
Synthesis in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Novel DMD Frameshift Variant (p.Leu2017Profs*5) in Spectrin-Like Repeat 16 Expands the Mutational Spectrum of DMD.Molecular genetics & genomic medicine · 2026Article
- Mitochondrial Dysfunction in Autism and Attention-Deficit/Hyperactivity Disorder: Evidence from Genetic, Biochemical, and Neuroimaging Approaches.Antioxidants (Basel, Switzerland) · 2026Review
- Applying an F-words lens to planning intervention for a child with autism: a retrospective case report with prospective follow-up.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diagnosis of ASD has increased globally owing to the expansion of diagnostic criteria, increased awareness, and improvement in symptom identification. However, the diagnosis of ASD in young or neurodivergent people remains challenging and requires the investigation of new early indications. Objectives: In this review, we examined the correlation between early hypotonia (including motor difficulties) and ASD, evaluating the potential of hypotonia as an early biomarker and screening instrument. Methods: Using the PRISMA criteria (PROSPERO: CRD42024626398), we searched PubMed, Embase, Cochrane Library, and Web of Science without any constraints on date or language. The inclusion criteria were derived from studies on children aged 0-6 years that investigated hypotonia (e.g., motor impairments or head lag) in connection with ASD diagnosis or characteristics. The eligible studies were prospective cohort, case-control, and retrospective video-analysis studies. Two researchers independently collected and evaluated the data. Results: Twenty-four studies (prospective cohort, case-control, or video analyses) were included in this review.The participants were aged 2 months to 6 years and included infant siblings of autistic children (a cohort with elevated likelihood of an autism diagnosis), children with familial ASD, and individuals from the general population.The research showed a consistent association of hypotonia and motor difficulties with ASD, despite variations in assessment methodologies, such as standardized motor measures and clinical evaluations. However, despite methodological heterogeneity, cumulative evidence supported the potential of hypotonia as an early ASD biomarker. Conclusion: Hypotonia and related motor differences may serve as practical screening indicators of increased likelihood of a later autism diagnosis. Identifying these signs can prompt earlier referral and support. While the findings are promising, further research is needed to standardize assessment protocols and validate clinical utility. Interdisciplinary collaboration may facilitate early detection, enhancing long-term outcomes through timely assistance. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier CRD42024626398.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.